ERBB2 and gastroesophageal junction adenocarcinoma: In 2014, ESMO published the results of a phase I clinical trial of PD-1 antibodies in advanced metastatic GC showing that 39 patients with a CRR of 22% and an ORR of 30% (27).The KEYNOTE-059 trial explored the efficacy and safety of first-line use of immunotherapy in Her-2 negative advanced GC or gastroesophageal junction adenocarcinoma (28).